ABT.SW Abbott Laboratories CHF100.00 pre-market 19 Feb 2026: Oversold bounce

ABT.SW stock opens pre-market at CHF100.00 on 19 Feb 2026 with an RSI of 4.70, an extreme oversold reading that often precedes a short-term bounce. Volume is thin at 40.00 shares on SIX so far, so any recovery may be fragile. Traders should watch the 50-day average CHF99.24 and the 200-day CHF102.26 for early confirmation. This report lays out valuation, technical triggers, Meyka AI grade, and a concise trade plan for an oversold-bounce approach.

ABT.SW stock pre-market snapshot and oversold signal

ABT.SW stock is quoted at CHF100.00 on the SIX exchange in Switzerland, up 1.01% pre-market from a previous close of CHF99.00. The key technical alarm is the RSI 4.70, a rare extreme that typically flags short-term mean reversion. MACD shows negative momentum with MACD -0.76 and signal -0.03, while ADX 97.96 indicates a strong directional move into oversold territory. Given the tiny traded volume 40.00 and average volume reported as 1.00, traders should treat early moves as low-liquidity and confirm with follow-through volume.

Valuation and fundamentals: PE, EPS, dividend and cash metrics

Abbott Laboratories (ABT.SW) trades at PE 34.84 with EPS CHF2.87, reflecting premium valuation versus the Healthcare sector average PE 34.32. Free cash flow per share is CHF3.95 and dividend per share is CHF2.51, giving a dividend yield near 1.94%. Price-to-sales is 5.09 and price-to-book is 4.45, consistent with a large medical-device and diagnostics leader. Current ratio 1.70 and interest coverage 20.22 show solid liquidity and low leverage, which matter when near-term sentiment reverts.

Technical analysis and oversold-bounce trade plan

The immediate technical setup supports a disciplined oversold-bounce strategy. Key levels: support at the year low CHF93.50, intraday pivot CHF100.00, and first resistance near the year high CHF106.00. Short-term target for a bounce is CHF106.00; a conservative stop-loss lies below CHF93.50 to limit downside. Use confirmation: a green candle on >2x recent volume or RSI rising above 30.00. Volatility (ATR CHF1.40) suggests tight risk sizing; aim for a risk:reward of at least 1:1.5 for swing trades.

Meyka AI grade, forecast model and price targets

Meyka AI rates ABT.SW with a score out of 100: 73.56 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a quarterly target CHF109.55 (+9.55% vs CHF100.00) and a yearly model price CHF100.56 (+0.56%). The monthly projection is CHF87.30 (-12.70%), showing near-term model sensitivity. Forecasts are model-based projections and not guarantees. For trading, we reference the quarterly CHF109.55 as an actionable upside target for a confirmed bounce.

Sector context, catalysts and risk drivers

ABT.SW sits in the Healthcare sector (Medical – Devices) where the sector average PE is 34.32 and average performance shows modest YTD strength. Catalysts: upcoming earnings on 15 Apr 2026, durable diagnostics demand, and seasonal device orders. Risks: thin SIX liquidity, higher valuation multiples, and execution on product rollouts. Macro risks include reimbursement pressure and currency moves between USD and CHF. Confirming sector strength can increase bounce odds; weakness across healthcare would raise the probability of further downside.

Practical trading rules for an oversold bounce on SIX

Enter only on clear confirmation: price above CHF101.00 on >2x local volume or RSI recovery to >30.00. Position size to limit downside to 1.00%–2.00% of portfolio per trade given ATR CHF1.40. Targets: first at CHF106.00, secondary near CHF109.55 (Meyka quarterly). Stop-loss: CHF93.50 or a volatility-adjusted stop at -1.5x ATR. Use limit orders due to thin trade depth and check SIX order book before execution. Link for company details and filings: Abbott investor site. For SIX market context see SIX Group market data.

Final Thoughts

Key takeaways for ABT.SW stock: the stock is priced at CHF100.00 pre-market on 19 Feb 2026 and shows an extreme oversold reading (RSI 4.70) that supports a disciplined oversold-bounce trade. Valuation is premium with PE 34.84 and stable cash metrics: free cash flow per share CHF3.95 and dividend per share CHF2.51. Meyka AI’s model projects a quarterly target CHF109.55 (+9.55%) and a yearly model CHF100.56 (+0.56%) versus the current price; these model outputs show a modest medium-term upside but mixed near-term signals (monthly CHF87.30, -12.70%). For traders we recommend waiting for confirmation: a volume-backed green candle or RSI recovery above 30.00 before adding. If confirmed, initial targets of CHF106.00 and CHF109.55 are reasonable, with a protective stop below CHF93.50. Forecasts are model-based projections and not guarantees. Meyka AI provides this as AI-powered market analysis; these insights combine technical triggers, fundamentals, and sector context to guide an oversold-bounce approach on SIX.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.